Redoxis is a Contract Research Organization (CRO) specializing in preclinical drug development, particularly in the evaluation of efficacy for treatments targeting autoimmune diseases. The company leverages its strong foundation in academic research to maintain an updated portfolio of preclinical models, focusing on inflammatory and autoimmune conditions such as rheumatoid arthritis, multiple sclerosis, and psoriasis. Redoxis offers a comprehensive range of services, including in vitro and ex vivo immunology assays, which encompass efficacy studies, mechanism of action (MoA) studies, and biomarker analysis. Their commitment to personalized communication and tailored study designs ensures that clients receive reliable and relevant results for their preclinical projects.

In addition to their core services, Redoxis conducts secondary analyses of biological samples, including pharmacokinetic studies, histology, and cytokine profiling. The organization prides itself on its ability to set up and validate models on demand, providing flexibility to meet specific research needs. With a dedicated team of experienced researchers, Redoxis aims to deliver high-quality preclinical studies that facilitate the investigation of therapeutic efficacy and mechanisms of action for novel therapies. Their ongoing expansion and recruitment efforts reflect their commitment to enhancing their capabilities and expertise in the field of immunology research.

Sweden

Redoxis is a preclinical boutique CRO specializing on inflammation and autoimmune conditions. We provide in vivo, ex vivo and in vitro preclinical efficacy and MoA studies. We have a fully equipped lab with capacity to perform a wide range of cell based assays as well as immunology assays to provide you everything form MoA studies to PK and in vivo efficacy studies.

Redoxis

Company Details